83 results on '"Maurel, J."'
Search Results
2. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
3. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial
4. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial
5. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study
6. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer
7. LBA2 POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (c-p) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy (Chemo)
8. Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer
9. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study
10. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer
11. Évolution des techniques de préparation des produits sanguins labiles (PSL) : inactivation des pathogènes dans les PSL
12. PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)
13. 512MO FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
14. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
15. Cellulite pelvienne sur bartholinite à streptocoque pyogènes : à propos d’un cas
16. LBA68 FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
17. 605P First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
18. 595P The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
19. Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO
20. Estado actual en el diagnóstico y el tratamiento de los sarcomas de partes blandas de las extremidades
21. Guía de práctica clínica en los tumores estromales gastrointestinales
22. 763P Combined gene signature (T-cell inflamed gene expression profile – TcellinfGEP – & IMMETCOLS) identifies a metabolic rewiring program, key for immune evasion
23. 433P Pre-treatment and post-treatment MRI extramural venous invasion, predicts disease-free survival and overall survival, in locally advanced rectal cancer
24. 383P An exosome-based liquid biopsy assay for predicting therapeutic outcomes in patients with metastatic colorectal cancer treated with anti-EGFR therapy: Results from prospective, first-line, PULSE and POSIBA trials
25. 352P Mutations of SMAD4 and FBXW7 predict poor outcome in TP53-driven metastatic colorectal cancer
26. 338P A new clinically applicable immune-metabolic signature (IMMETCOLS) reveals metabolic singularities in consensus molecular subtypes (CMS) in colorectal cancer
27. Registro hospitalario de tumoraciones pancreáticas. Experiencia del Hospital Clínic de Barcelona
28. Impact of Microscopic Incomplete Resection for Colorectal Liver Metastases on Surgical Margin Recurrence: R1-Contact vs. R1≪1mm Margin Width
29. Evaluación de la eficacia y eficiencia de una unidad multidisciplinaria para la atención de pacientes con cáncer colorrectal
30. Fistules intestinales tardives après implantation de prothèse pariétale abdominale
31. 996P An immune-metabolic signature correlates with immune-suppressive patterns and with outcome, across tumor types
32. 442P A phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients. GEMCAD 16-02 (AVEVAC trial)
33. 416P Randomized phase II trial of second-line FOLFIRI-panitumumab vs FOLFIRI alone in Ras wild type (wt) metastatic colorectal cancer (mCRC) patients beyond progression to first-line FOLFOX-panitumumab: BEYOND study (GEMCAD 17-01)
34. 81P Baseline circulating CD4+PD1+high T cells (TCD4PD1H) as predictors of survival in patients (P) with solid tumors treated with immune-checkpoint inhibitors (ICI)
35. P-228 Phase II multicentric randomized controlled trial to compare first-line treatment with FOLFOX6m + mAB alone or in combination with liver chemoembolization (Lifepearls-Irinotecan) in poor prognosis colorectal cancer with liver-limited disease
36. Capítulo 139 - Tratamientos médicos en oncología
37. Capítulo 140 - Estrategia diagnóstica y terapéutica en los principales tumores sólidos
38. 548P Molecular pre-screening using comprehensive gene panels offered by clinical trials (CT)
39. 471P Identification and validation of a new prognostic score in metastatic colorectal cancer (mCRC): GEMCAD score
40. 476P Mutational profiling allows the stratification of metastatic colorectal cancer patients with poor prognosis
41. 474P Prognostic and predictive role of Consensus Molecular Subtypes (CMS) determined by immunohistochemistry in metastatic colorectal cancer (mCRC)
42. 427P Value of magnetic resonance diffusion weighted imaging in the identification of complete responder patients with rectal cancer treated with neoadjuvant therapy
43. 109P Subpopulations of peripheral blood lymphocytes and response to immunotherapy across cancer-types
44. Capítulo 9 - Tratamiento médico del cáncer de páncreas
45. PD-031 - Immune signatures identify three immune clusters in mCRC, with potential clinical implications
46. PD-011 - Mutational profile of non-metastatic anal squamous cell carcinoma: a restrictive high impact genetic variants analysis
47. P-314 - Do we need adjuvant therapy in patients with rectal cancer and pathologic complete response, after conventional preoperative chemoradiation and laparoscopic (LapTME) or Transanal total mesorectal excision (TaTME)?
48. P-191 - Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND)
49. P-163 - Whole-exome sequencing of non-metastatic anal squamous cell carcinoma: a prognostic genetic variants analysis
50. O-002 - Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.